AbbVie Inc. (NYSE:ABBV) Traded 8.1% Above Its 50 Day Average

About shares traded. AbbVie Inc (NYSE:ABBV) has risen 10.63% since October 13, 2016 and is uptrending. The stock rose 0.81% or $0.74 reaching $91.91.

About 370,471 shares traded.

Analysts await AbbVie Inc (NYSE:ABBV) to report earnings on October, 27. It has underperformed by 6.07% the S&P500. Raymond James Na reported 0.95% stake. (CSCO) by 22.25% based on its latest 2017Q2 regulatory filing with the SEC. Given the stock's recent action, it seemed like a good time to take a closer look at the company's recent data. Pzena Mgmt Limited Liability Corp reported 5,137 shares or 0% of all its holdings. Abbvie Inc now has $146.51 billion valuation. The stock rose 0.77% or $0.26 reaching $33.51. Institute For Wealth Mgmt Limited Co holds 14,509 shares. Unilever NV (ADR) (NYSE:UN) has risen 26.55% since October 13, 2016 and is uptrending. CIBC Asset Management Inc's holdings in AbbVie were worth $16,443,000 at the end of the most recent quarter. On Monday, May 2 the stock rating was downgraded by Johnson Rice to "Hold". The 12-month price target is $70.22 with 4 firms rating the stock a strong buy, 10 brokers rating the stock a buy, 5 brokers rating the stock a hold, one equity analyst rating the company a underperform, and lastly zero analysts rating the company a sell. Therefore 56% are positive. Zacks Investment Research cut AbbVie from a "hold" rating to a "sell" rating in a research report on Tuesday, July 4th. BidaskClub upgraded shares of AbbVie from a "buy" rating to a "strong-buy" rating in a report on Wednesday, September 6th. The firm has "Buy" rating given on Friday, August 19 by SunTrust. The stock of AbbVie Inc (NYSE:ABBV) earned "Buy" rating by Goldman Sachs on Monday, March 7. Jefferies Group LLC reiterated a "buy" rating and issued a $94.00 price target on shares of AbbVie in a report on Friday, September 8th. As per Friday, November 13, the company rating was initiated by Citigroup. As per Wednesday, June 8, the company rating was downgraded by Morgan Stanley. BMO Capital Markets has "Hold" rating and $63 target. As per Tuesday, October 18, the company rating was initiated by Leerink Swann. The value of the company's investment in AbbVie Inc. increased from $1,679,000 to $2,971,000 a change of $1,292,000 quarter to quarter. Its up 0.01, from 0.99 in 2017Q1.

Traders are a little more bullish on shares of AbbVie Inc. considering the decrease in short interest. Penobscot Investment accumulated 93,040 shares. Brandywine Global Invest Mgmt Limited Liability Corp owns 2.15 million shares or 0.99% of their U.S. portfolio. Bainco holds 1.53% of its portfolio in AbbVie Inc (NYSE:ABBV) for 140,650 shares. Investors of record on Friday, October 13th will be given a dividend of $0.64 per share. Van Eck invested 0.08% of its portfolio in AbbVie Inc (NYSE:ABBV). Davenport And Commerce Limited Com reported 110,853 shares stake. Catalyst Advsr Limited stated it has 3,927 shares. Following the transaction, the director now directly owns 15,498 shares in the company, valued at $1,091,834.10. Mcdaniel Terry & Co has invested 0.26% in AbbVie Inc (NYSE:ABBV). Connecticut-based Essex Fincl Svcs Inc has invested 0.56% in AbbVie Inc (NYSE:ABBV). Institutional owners hold 70.80% stake in the company while Insiders ownership held at 0.10%. The dividend will be $0.640 per share for the quarter which is $2.56 annualized. BlackRock Inc. now owns 94,074,962 shares of the company's stock valued at $6,821,375,000 after purchasing an additional 1,864,418 shares during the period. Ahl Ptnrs Ltd Liability Partnership accumulated 77,053 shares or 0.12% of the stock.

Since May 4, 2017, it had 0 insider buys, and 5 selling transactions for $18.84 million activity. Also, VP Robert A. Michael sold 6,699 shares of the stock in a transaction dated Thursday, September 28th. Schumacher Laura J sold 79,800 shares worth $5.59M. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company's stock valued at $921,233,000 after purchasing an additional 3,340,038 shares during the period. The Ingalls & Snyder Llc holds 337,700 shares with $21.64M value, up from 329,863 last quarter. It increased, as 56 investors sold MRK shares while 612 reduced holdings. The shares were sold at an average price of $65.35, for a total transaction of $2,502,905.00. The value of the position overall is up by 22.5%. The ex-dividend date is Thursday the 12th of October 2017. Analysts expect next quarter's EPS to be $1.43 with next year's EPS projected to be $6.55. ARNC's profit would be $124.15 million giving it 24.61 P/E if the $0.28 EPS is correct. After $1.42 actual earnings per share reported by AbbVie Inc for the previous quarter, Wall Street now forecasts -3.52% negative EPS growth. (NASDAQ:CSCO) or 92,840 shares.

Investors sentiment increased to 1.07 in 2017 Q2. Its up 0.01, from 0.99 in 2017Q1. It improved, as 90 investors sold CSCO shares while 594 reduced holdings. Finally, Orbis Allan Gray Ltd raised its position in shares of AbbVie by 35.7% in the second quarter. Hanson & Doremus Invest Mngmt, a Vermont-based fund reported 5,609 shares. Sonata Capital Grp Inc Inc holds 0.21% or 3,820 shares in its portfolio. 85,513 were reported by Bancorpsouth. Weybosset & Mngmt Llc reported 4,700 shares stake. M Kraus & stated it has 0.33% in Merck & Co., Inc. (NYSE:KBR). Deutsche Natl Bank Ag reported 480,958 shares. Heartland holds 446,603 shares or 0.44% of its portfolio. Bancshares Of Nova Scotia Com holds 10,899 shares. Boston Family Office Ltd Liability Corporation holds 0.81% in Merck & Co., Inc. Sigma Planning invested 0.35% of its portfolio in Cisco Systems, Inc.